-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical’s esmolol hydrochloride injection was approved as a supplementary application.
According to data from Meinenet, the sales of terminal esmolol hydrochloride injection in China’s public medical institutions exceeded 7 in 2020.
100 million yuan mark, 2021H1 increased by more than 50% year-on-year
.
Since the beginning of this year, Qilu has reviewed more than 40 products
.
According to data from Meinenet, the sales of terminal esmolol hydrochloride injection in China’s public medical institutions exceeded 7 in 2020.
100 million yuan mark, 2021H1 increased by more than 50% year-on-year
.
Since the beginning of this year, Qilu has reviewed more than 40 products
.
On November 24, 2021, the drug approval document pending information is released
Information, esmolol ultrashort β- adrenergic blocking effect, is the treatment of ventricular tachyarrhythmias, acute myocardial ischemia and postoperative blood pressure like an ideal drug
.
.
Sales of terminal esmolol hydrochloride injection in Chinese public medical institutions in recent years (unit: 100 million yuan)
Source: The terminal competition pattern of China's public medical institutions
According to data from Menet.
com, in recent years , the sales of terminal esmolol hydrochloride injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly, and will exceed 700 million yuan in 2020.
In 2021H1, a year-on-year growth of more than 50%, Qilu Pharmaceutical has the largest market share
.
com, in recent years , the sales of terminal esmolol hydrochloride injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly, and will exceed 700 million yuan in 2020.
In 2021H1, a year-on-year growth of more than 50%, Qilu Pharmaceutical has the largest market share
.
For Esmolol Hydrochloride Injection, 10 companies have production approvals.
In terms of consistency evaluation, 3 companies have reviewed it.
Among them, Qilu Pharmaceutical (Hainan) and Qilu Pharmaceutical have been approved as supplementary applications
.
In terms of consistency evaluation, 3 companies have reviewed it.
Among them, Qilu Pharmaceutical (Hainan) and Qilu Pharmaceutical have been approved as supplementary applications
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Up to now, Qilu has reviewed more than 90 products, including 7 cardiovascular system drugs, Levosimendan injection is an exclusive review, isosorbide mononitrate sustained-release tablets, fasudil hydrochloride injection, hydrochloric acid Trimetazidine sustained-release tablets were the first to be reviewed
.
It is worth mentioning that since this year, Qilu has reviewed more than 40 products
.
.
It is worth mentioning that since this year, Qilu has reviewed more than 40 products
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
A few days ago, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical’s esmolol hydrochloride injection was approved as a supplementary application.
According to data from Meinenet, the sales of terminal esmolol hydrochloride injection in China’s public medical institutions exceeded 7 in 2020.
100 million yuan mark, 2021H1 increased by more than 50% year-on-year
.
Since the beginning of this year, Qilu has reviewed more than 40 products
.
According to data from Meinenet, the sales of terminal esmolol hydrochloride injection in China’s public medical institutions exceeded 7 in 2020.
100 million yuan mark, 2021H1 increased by more than 50% year-on-year
.
Since the beginning of this year, Qilu has reviewed more than 40 products
.
On November 24, 2021, the drug approval document pending information is released
Information, esmolol ultrashort β- adrenergic blocking effect, is the treatment of ventricular tachyarrhythmias, acute myocardial ischemia and postoperative blood pressure like an ideal drug
.
.
Sales of terminal esmolol hydrochloride injection in Chinese public medical institutions in recent years (unit: 100 million yuan)
Source: The terminal competition pattern of China's public medical institutions
According to data from Menet.
com, in recent years , the sales of terminal esmolol hydrochloride injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly, and will exceed 700 million yuan in 2020.
In 2021H1, a year-on-year growth of more than 50%, Qilu Pharmaceutical has the largest market share
.
com, in recent years , the sales of terminal esmolol hydrochloride injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly, and will exceed 700 million yuan in 2020.
In 2021H1, a year-on-year growth of more than 50%, Qilu Pharmaceutical has the largest market share
.
For Esmolol Hydrochloride Injection, 10 companies have production approvals.
In terms of consistency evaluation, 3 companies have reviewed it.
Among them, Qilu Pharmaceutical (Hainan) and Qilu Pharmaceutical have been approved as supplementary applications
.
In terms of consistency evaluation, 3 companies have reviewed it.
Among them, Qilu Pharmaceutical (Hainan) and Qilu Pharmaceutical have been approved as supplementary applications
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Up to now, Qilu has reviewed more than 90 products, including 7 cardiovascular system drugs, Levosimendan injection is an exclusive review, isosorbide mononitrate sustained-release tablets, fasudil hydrochloride injection, hydrochloric acid Trimetazidine sustained-release tablets were the first to be reviewed
.
It is worth mentioning that since this year, Qilu has reviewed more than 40 products
.
.
It is worth mentioning that since this year, Qilu has reviewed more than 40 products
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
A few days ago, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical’s esmolol hydrochloride injection was approved as a supplementary application.
According to data from Meinenet, the sales of terminal esmolol hydrochloride injection in China’s public medical institutions exceeded 7 in 2020.
100 million yuan mark, 2021H1 increased by more than 50% year-on-year
.
Since the beginning of this year, Qilu has reviewed more than 40 products
.
According to data from Meinenet, the sales of terminal esmolol hydrochloride injection in China’s public medical institutions exceeded 7 in 2020.
100 million yuan mark, 2021H1 increased by more than 50% year-on-year
.
Since the beginning of this year, Qilu has reviewed more than 40 products
.
On November 24, 2021, the drug approval document pending information is released
Information, esmolol ultrashort β- adrenergic blocking effect, is the treatment of ventricular tachyarrhythmias, acute myocardial ischemia and postoperative blood pressure like an ideal drug
.
Hypertension hypertension hypertension.
Sales of terminal esmolol hydrochloride injection in Chinese public medical institutions in recent years (unit: 100 million yuan)
Source: The terminal competition pattern of China's public medical institutions
According to data from Menet.
com, in recent years , the sales of terminal esmolol hydrochloride injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly, and will exceed 700 million yuan in 2020.
In 2021H1, a year-on-year growth of more than 50%, Qilu Pharmaceutical has the largest market share
.
Hospital hospital hospitalcom, in recent years , the sales of terminal esmolol hydrochloride injection in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly, and will exceed 700 million yuan in 2020.
In 2021H1, a year-on-year growth of more than 50%, Qilu Pharmaceutical has the largest market share
.
For Esmolol Hydrochloride Injection, 10 companies have production approvals.
In terms of consistency evaluation, 3 companies have reviewed it.
Among them, Qilu Pharmaceutical (Hainan) and Qilu Pharmaceutical have been approved as supplementary applications
.
Enterprise business enterpriseIn terms of consistency evaluation, 3 companies have reviewed it.
Among them, Qilu Pharmaceutical (Hainan) and Qilu Pharmaceutical have been approved as supplementary applications
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Up to now, Qilu has reviewed more than 90 products, including 7 cardiovascular system drugs, Levosimendan injection is an exclusive review, isosorbide mononitrate sustained-release tablets, fasudil hydrochloride injection, hydrochloric acid Trimetazidine sustained-release tablets were the first to be reviewed
.
It is worth mentioning that since this year, Qilu has reviewed more than 40 products
.
.
It is worth mentioning that since this year, Qilu has reviewed more than 40 products
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
